Annual Net Income
-$3.55 M
-$6.79 M-209.56%
01 December 2023
Summary:
COSCIENS Biopharma annual net profit is currently -$3.55 million, with the most recent change of -$6.79 million (-209.56%) on 01 December 2023. During the last 3 years, it has fallen by -$5.01 million (-343.91%).CSCI Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$5.75 M
-$4.33 M-304.71%
01 September 2024
Summary:
COSCIENS Biopharma quarterly net profit is currently -$5.75 million, with the most recent change of -$4.33 million (-304.71%) on 01 September 2024. Over the past year, it has dropped by -$4.98 million (-641.62%).CSCI Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$10.21 M
-$4.98 M-95.27%
01 September 2024
Summary:
COSCIENS Biopharma TTM net profit is currently -$10.21 million, with the most recent change of -$4.98 million (-95.27%) on 01 September 2024. Over the past year, it has dropped by -$8.14 million (-394.29%).CSCI TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CSCI Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -209.6% | -641.6% | -394.3% |
| 3 y3 years | -343.9% | -938.7% | -881.2% |
| 5 y5 years | -1432.3% | -7259.3% | -1534.7% |
CSCI Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -200.1% | -334.7% | -289.0% |
COSCIENS Biopharma Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$5.75 M(+304.7%) | -$10.21 M(+95.3%) |
| June 2024 | - | -$1.42 M(+1.7%) | -$5.23 M(+12.0%) |
| Mar 2024 | - | -$1.40 M(-14.1%) | -$4.66 M(+31.4%) |
| Dec 2023 | -$3.55 M(-209.6%) | -$1.63 M(+110.0%) | -$3.55 M(+71.9%) |
| Sept 2023 | - | -$776.00 K(-9.8%) | -$2.06 M(+275.6%) |
| June 2023 | - | -$860.00 K(+202.1%) | -$549.70 K(-132.1%) |
| Mar 2023 | - | -$284.70 K(+97.8%) | $1.71 M(-50.4%) |
| Dec 2022 | $3.24 M(+22.8%) | -$143.90 K(-119.5%) | $3.45 M(-25.2%) |
| Sept 2022 | - | $738.90 K(-47.3%) | $4.61 M(+1.2%) |
| June 2022 | - | $1.40 M(-3.5%) | $4.56 M(+23.1%) |
| Mar 2022 | - | $1.45 M(+42.5%) | $3.70 M(+39.3%) |
| Dec 2021 | $2.64 M(+81.3%) | $1.02 M(+48.5%) | $2.66 M(+103.6%) |
| Sept 2021 | - | $686.20 K(+25.8%) | $1.31 M(+71.1%) |
| June 2021 | - | $545.60 K(+33.8%) | $763.30 K(-24.1%) |
| Mar 2021 | - | $407.90 K(-222.3%) | $1.01 M(-27.7%) |
| Dec 2020 | $1.46 M(-267.9%) | -$333.40 K(-332.8%) | $1.39 M(-24.3%) |
| Sept 2020 | - | $143.20 K(-81.8%) | $1.84 M(+13.7%) |
| June 2020 | - | $788.60 K(-0.7%) | $1.62 M(+300.3%) |
| Mar 2020 | - | $794.00 K(+596.5%) | $404.30 K(-146.7%) |
| Dec 2019 | -$867.10 K(+274.2%) | $114.00 K(-245.8%) | -$866.50 K(+38.8%) |
| Sept 2019 | - | -$78.20 K(-81.6%) | -$624.30 K(-19.7%) |
| June 2019 | - | -$425.50 K(-10.8%) | -$777.30 K(+62.7%) |
| Mar 2019 | - | -$476.80 K(-233.9%) | -$477.80 K(+108.1%) |
| Dec 2018 | -$231.70 K(-69.6%) | $356.20 K(-254.1%) | -$229.60 K(-87.9%) |
| Sept 2018 | - | -$231.20 K(+83.5%) | -$1.90 M(+32.8%) |
| June 2018 | - | -$126.00 K(-44.9%) | -$1.43 M(+40.3%) |
| Mar 2018 | - | -$228.60 K(-82.6%) | -$1.02 M(+31.1%) |
| Dec 2017 | -$762.00 K(-128.3%) | -$1.31 M(-651.1%) | -$776.80 K(-235.8%) |
| Sept 2017 | - | $238.30 K(-16.3%) | $571.90 K(-30.6%) |
| June 2017 | - | $284.80 K(+2041.4%) | $824.20 K(-54.3%) |
| Mar 2017 | - | $13.30 K(-62.5%) | $1.80 M(-33.8%) |
| Dec 2016 | $2.69 M(-24.1%) | $35.50 K(-92.8%) | $2.73 M(-47.0%) |
| Sept 2016 | - | $490.60 K(-61.2%) | $5.14 M(-4.8%) |
| June 2016 | - | $1.26 M(+35.3%) | $5.40 M(+15.7%) |
| Mar 2016 | - | $934.80 K(-61.9%) | $4.67 M(+30.4%) |
| Dec 2015 | $3.55 M(+158.4%) | $2.45 M(+227.0%) | $3.58 M(+209.0%) |
| Sept 2015 | - | $749.70 K(+41.5%) | $1.16 M(+12.8%) |
| June 2015 | - | $529.90 K(-446.6%) | $1.03 M(-5.6%) |
| Mar 2015 | - | -$152.90 K(-586.9%) | $1.09 M(-22.4%) |
| Dec 2014 | $1.37 M(+731.6%) | $31.40 K(-94.9%) | $1.40 M(+10.9%) |
| Sept 2014 | - | $618.20 K(+4.7%) | $1.26 M(+65.3%) |
| June 2014 | - | $590.50 K(+267.9%) | $764.40 K(-1270.6%) |
| Mar 2014 | - | $160.50 K(-251.4%) | -$65.30 K(-137.2%) |
| Dec 2013 | $165.10 K(-130.5%) | -$106.00 K(-188.8%) | $175.40 K(+283.8%) |
| Sept 2013 | - | $119.40 K(-149.9%) | $45.70 K(-121.5%) |
| June 2013 | - | -$239.20 K(-159.6%) | -$212.40 K(+62.1%) |
| Mar 2013 | - | $401.20 K(-270.2%) | -$131.00 K(-75.5%) |
| Dec 2012 | -$541.20 K(-195.7%) | -$235.70 K(+69.9%) | -$535.70 K(+1011.4%) |
| Sept 2012 | - | -$138.70 K(-12.1%) | -$48.20 K(+259.7%) |
| June 2012 | - | -$157.80 K(+4408.6%) | -$13.40 K(-105.3%) |
| Mar 2012 | - | -$3500.00(-101.4%) | $251.30 K(-57.7%) |
| Dec 2011 | $565.70 K(+22.0%) | $251.80 K(-342.3%) | $594.30 K(+13.3%) |
| Sept 2011 | - | -$103.90 K(-197.2%) | $524.70 K(-27.5%) |
| June 2011 | - | $106.90 K(-68.5%) | $723.90 K(-14.2%) |
| Mar 2011 | - | $339.50 K(+86.3%) | $843.40 K(+84.0%) |
| Dec 2010 | $463.60 K | $182.20 K(+91.2%) | $458.30 K(-243.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | $95.30 K(-57.9%) | -$318.80 K(-23.6%) |
| June 2010 | - | $226.40 K(-596.5%) | -$417.40 K(+72.1%) |
| Mar 2010 | - | -$45.60 K(-92.3%) | -$242.50 K(+110.0%) |
| Dec 2009 | -$66.20 K(-97.8%) | -$594.90 K(>+9900.0%) | -$115.50 K(-72.2%) |
| Sept 2009 | - | -$3300.00(-100.8%) | -$415.50 K(-52.4%) |
| June 2009 | - | $401.30 K(+393.0%) | -$872.80 K(-62.7%) |
| Mar 2009 | - | $81.40 K(-109.1%) | -$2.34 M(-22.3%) |
| Dec 2008 | -$2.96 M(+110.8%) | -$894.90 K(+94.3%) | -$3.02 M(+13.5%) |
| Sept 2008 | - | -$460.60 K(-56.9%) | -$2.66 M(-5.2%) |
| June 2008 | - | -$1.07 M(+80.7%) | -$2.80 M(+43.2%) |
| Mar 2008 | - | -$591.30 K(+10.4%) | -$1.96 M(+41.4%) |
| Dec 2007 | -$1.40 M(+500.3%) | -$535.80 K(-11.6%) | -$1.38 M(+46.2%) |
| Sept 2007 | - | -$606.30 K(+172.1%) | -$946.40 K(+122.0%) |
| June 2007 | - | -$222.80 K(+1085.1%) | -$426.30 K(+106.3%) |
| Mar 2007 | - | -$18.80 K(-80.9%) | -$206.60 K(-10.9%) |
| Dec 2006 | -$233.70 K(+376.0%) | -$98.50 K(+14.3%) | -$231.80 K(+727.9%) |
| Sept 2006 | - | -$86.20 K(+2680.6%) | -$28.00 K(-42.7%) |
| June 2006 | - | -$3100.00(-93.0%) | -$48.90 K(-232.2%) |
| Mar 2006 | - | -$44.00 K(-141.8%) | $37.00 K(-176.6%) |
| Dec 2005 | -$49.10 K(-85.2%) | $105.30 K(-198.3%) | -$48.30 K(-79.1%) |
| Sept 2005 | - | -$107.10 K(-229.3%) | -$230.80 K(-43.7%) |
| June 2005 | - | $82.80 K(-164.0%) | -$410.10 K(-24.9%) |
| Mar 2005 | - | -$129.30 K(+67.5%) | -$546.40 K(+65.0%) |
| Dec 2004 | -$330.90 K(-197.1%) | -$77.20 K(-73.0%) | -$331.20 K(-3.3%) |
| Sept 2004 | - | -$286.40 K(+435.3%) | -$342.40 K(-281.6%) |
| June 2004 | - | -$53.50 K(-162.3%) | $188.50 K(-53.5%) |
| Mar 2004 | - | $85.90 K(-197.2%) | $405.60 K(+19.3%) |
| Dec 2003 | $340.90 K(+363.8%) | -$88.40 K(-136.2%) | $339.90 K(-27.6%) |
| Sept 2003 | - | $244.50 K(+49.4%) | $469.50 K(+63.5%) |
| June 2003 | - | $163.60 K(+709.9%) | $287.10 K(+59.6%) |
| Mar 2003 | - | $20.20 K(-51.0%) | $179.90 K(+135.5%) |
| Dec 2002 | $73.50 K(-133.8%) | $41.20 K(-33.7%) | $76.40 K(-48.4%) |
| Sept 2002 | - | $62.10 K(+10.1%) | $148.10 K(+659.5%) |
| June 2002 | - | $56.40 K(-167.7%) | $19.50 K(-108.8%) |
| Mar 2002 | - | -$83.30 K(-173.8%) | -$221.40 K(-1.6%) |
| Dec 2001 | -$217.40 K(-64.4%) | $112.90 K(-269.8%) | -$224.90 K(-64.1%) |
| Sept 2001 | - | -$66.50 K(-64.0%) | -$627.20 K(+1.9%) |
| June 2001 | - | -$184.50 K(+112.6%) | -$615.80 K(+8.7%) |
| Mar 2001 | - | -$86.80 K(-70.0%) | -$566.30 K(-8.2%) |
| Dec 2000 | -$610.80 K(-1.7%) | -$289.40 K(+425.2%) | -$617.20 K(-17.1%) |
| Sept 2000 | - | -$55.10 K(-59.2%) | -$744.90 K(-1.7%) |
| June 2000 | - | -$135.00 K(-2.0%) | -$757.90 K(+9.7%) |
| Mar 2000 | - | -$137.70 K(-67.0%) | -$690.70 K(+11.5%) |
| Dec 1999 | -$621.40 K(-93.3%) | -$417.10 K(+512.5%) | -$619.30 K(-85.7%) |
| Sept 1999 | - | -$68.10 K(+0.4%) | -$4.32 M(-52.5%) |
| June 1999 | - | -$67.80 K(+2.3%) | -$9.10 M(-0.0%) |
| Mar 1999 | - | -$66.30 K(-98.4%) | -$9.10 M(-2.3%) |
| Dec 1998 | -$9.29 M(-32.8%) | -$4.12 M(-15.0%) | -$9.32 M(-36.0%) |
| Sept 1998 | - | -$4.85 M(+7018.5%) | -$14.55 M(+30.5%) |
| June 1998 | - | -$68.10 K(-75.8%) | -$11.15 M(-11.5%) |
| Mar 1998 | - | -$281.80 K(-97.0%) | -$12.60 M(-8.5%) |
| Dec 1997 | -$13.84 M(+412.5%) | -$9.35 M(+545.7%) | -$13.77 M(+211.6%) |
| Sept 1997 | - | -$1.45 M(-4.8%) | -$4.42 M(+48.7%) |
| June 1997 | - | -$1.52 M(+4.9%) | -$2.97 M(+104.9%) |
| Mar 1997 | - | -$1.45 M | -$1.45 M |
| Dec 1996 | -$2.70 M | - | - |
FAQ
- What is COSCIENS Biopharma annual net profit?
- What is the all time high annual net income for COSCIENS Biopharma?
- What is COSCIENS Biopharma annual net income year-on-year change?
- What is COSCIENS Biopharma quarterly net profit?
- What is the all time high quarterly net income for COSCIENS Biopharma?
- What is COSCIENS Biopharma quarterly net income year-on-year change?
- What is COSCIENS Biopharma TTM net profit?
- What is the all time high TTM net income for COSCIENS Biopharma?
- What is COSCIENS Biopharma TTM net income year-on-year change?
What is COSCIENS Biopharma annual net profit?
The current annual net income of CSCI is -$3.55 M
What is the all time high annual net income for COSCIENS Biopharma?
COSCIENS Biopharma all-time high annual net profit is $3.55 M
What is COSCIENS Biopharma annual net income year-on-year change?
Over the past year, CSCI annual net profit has changed by -$6.79 M (-209.56%)
What is COSCIENS Biopharma quarterly net profit?
The current quarterly net income of CSCI is -$5.75 M
What is the all time high quarterly net income for COSCIENS Biopharma?
COSCIENS Biopharma all-time high quarterly net profit is $2.45 M
What is COSCIENS Biopharma quarterly net income year-on-year change?
Over the past year, CSCI quarterly net profit has changed by -$4.98 M (-641.62%)
What is COSCIENS Biopharma TTM net profit?
The current TTM net income of CSCI is -$10.21 M
What is the all time high TTM net income for COSCIENS Biopharma?
COSCIENS Biopharma all-time high TTM net profit is $5.40 M
What is COSCIENS Biopharma TTM net income year-on-year change?
Over the past year, CSCI TTM net profit has changed by -$8.14 M (-394.29%)